The association of Alzheimer's disease and related dementias blood‐based biomarkers with depressive symptoms
Alzheimer's & Dementia · 2026
DOI: 10.1002/alz.71007 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alzheimer's & Dementia, 2026. Verfasst von Julia R Bacci und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology and Prevention, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA. Hauptthemen laut MEDLINE: Depression, Alzheimer Disease, Glial Fibrillary Acidic Protein, Dementia. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS, NCI NIH HHS, National Health and Medical Research Council of Australia.
Themen: Depression, Demenz
Abstract (Originalsprache)
INTRODUCTION Depressive symptoms are common in older adults and have been associated with the risk of Alzheimer's disease/Alzheimer's disease and related dementias (AD/ADRD), but the mechanisms and biomarkers underlying this association remain unclear. METHODS We included baseline data from 11,947 non‐demented adults aged ≥ 70 years at enrollment in the Aspirin in Reducing Events in the Elderly (ASPREE) clinical trial. Linear regressions were used to examine cross‐sectional associations between AD/ADRD blood‐based biomarkers (BBMs) and baseline depressive symptoms. Interactions between sex or apolipoprotein E ( APOE ) ε4 carrier status and BBMs were examined. RESULTS Higher glial fibrillary acidic protein (GFAP) was associated with higher depressive symptoms. We did not observe an association between amyloid beta 42/40 ratio, phosphorylated tau181, or neurofilament light chain with depressive symptoms; interactions between sex or APOE ε4 with depressive symptoms were not significant. DISCUSSION In this large, community‐based cohort of older adults, plasma GFAP was associated with greater depressive symptoms. Highlights Plasma glial fibrillary acidic protein was associated with depressive symptoms. Neuroinflammation may underlie depressive symptoms in this group. Future research is needed to examine sex differences in this association.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Epidemiology and Prevention, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
- School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
- Division of Geriatric and Palliative Medicine, Department of Medicine, Hennepin Healthcare, Minneapolis, Minnesota, USA.
- Berman Center for Outcomes and Clinical Research, Hennepin Healthcare Research Institute, Minneapolis, Minnesota, USA.
- The Institute for Mental and Physical Health and Clinical Translation (IMPACT), School of Medicine, Deakin University, Geelong, Victoria, Australia.
ORCID-Profile: Michelle M Mielke
Förderung
- NIA NIH HHS
- NCI NIH HHS
- National Health and Medical Research Council of Australia
- Victorian Cancer Agency
- Monash University
- National Institute on Aging
- National Cancer Institute
Zitieren
APA
Bacci, J. R., Ryan, J., Murray, A. M., Wu, Z., Woods, R. L., Berk, M., & Mielke, M. M. (2026). The association of Alzheimer's disease and related dementias blood‐based biomarkers with depressive symptoms. Alzheimer's & Dementia. https://doi.org/10.1002/alz.71007
Vancouver
Bacci JR, Ryan J, Murray AM, Wu Z, Woods RL, Berk M, et al. The association of Alzheimer's disease and related dementias blood‐based biomarkers with depressive symptoms. Alzheimer's & Dementia. 2026. doi:10.1002/alz.71007
BibTeX
@article{Bacci2026,
author = {Bacci, Julia R and Ryan, Joanne and Murray, Anne M and Wu, Zimu and Woods, Robyn L and Berk, Michael and Mielke, Michelle M},
title = {The association of Alzheimer's disease and related dementias blood‐based biomarkers with depressive symptoms},
journal = {Alzheimer's & Dementia},
year = {2026},
doi = {10.1002/alz.71007}
}
EUVIMED